Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024244 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2599506 in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT01024244: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT01024244 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01024244, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to help answer the following questions: * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. * To determine how much LY2599506 should be given to participants. * To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.
Primary Outcome
Change in HbA1c from baseline following 12 weeks of therapy (HbA1c at week 12 minus HbA1c at baseline). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Interventions
- DRUG Placebo
- DRUG LY2599506
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Why NCT01024244 stopped before completion
NCT01024244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01024244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01024244 about?
NCT01024244 is a clinical study titled "A Study of LY2599506 in Patients With Type 2 Diabetes". The purpose of this study is to help answer the following questions: * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control b...
What is the current status of trial NCT01024244?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01024244?
The interventions under investigation include: Placebo (DRUG), LY2599506 (DRUG).
Who is sponsoring clinical trial NCT01024244?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia